You can receive insights into any symbol that we track. You'll see relevant statistics, signals, pricing data, etc.
Business Units or Product Lines |
Regeneron Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for serious medical conditions. Its key product lines include EYLEA (aflibercept) Injection for ophthalmologic diseases, Dupixent (dupilumab) for asthma, atopic dermatitis, and other inflammatory conditions, and Libtayo (cemiplimab) for certain types of skin cancers. The pipeline also includes various investigational products in oncology, ophthalmology, and immunology. |
Business Models for Each Product Line |
Regeneron generates revenue primarily through the sale of its marketed products such as EYLEA, Dupixent, and Libtayo. It also has collaboration agreements with companies like Sanofi, which contribute to revenues through shared profits and royalties. Major expense categories include research and development, especially for clinical trials and drug discovery, as well as sales and marketing expenses to support product commercialization. |
Future Opportunities for Growth |
Opportunities for growth include expanding indications for existing drugs like Dupixent in additional inflammatory diseases, pursuing new treatments in their oncology and genetic medicines pipelines, and leveraging their proprietary VelociSuite technologies to discover innovative therapies. Growth may also come from expanding their geographic market reach for existing products. |
Potential Major Risks |
Major risks include regulatory hurdles for pipeline products, competition from other pharmaceutical companies with rival medications, potential changes in healthcare regulations affecting drug pricing, and reliance on the success of key collaborations such as with Sanofi. Moreover, the loss of patent exclusivity for major products like EYLEA could impact future revenues. |
Learn More about Regeneron Pharmaceuticals, Inc.:
Company Insights by Algobear (ChatGPT);
Tell me more about Regeneron Pharmaceuticals, Inc.'s latest earnings (REGN:Nasdaq)
Who are some of Regeneron Pharmaceuticals, Inc.'s competitors? (REGN:Nasdaq)
Are analysts bullish on Regeneron Pharmaceuticals, Inc.? Please show it in a table format. (REGN:Nasdaq)
Also read:
https://finance.yahoo.com/REGN/profile
| Market Cap-Display | Market Cap-Actual | Market Cap | Enterprise Value-Display | Enterprise Value-Actual | Enterprise Value | Trailing P/E | Forward P/E | PEG Ratio (5yr expected) | Price/Sales | Price/Book | Enterprise Value/Revenue | Enterprise Value/EBITDA | Profit Margin | Operating Margin | Return on Assets | Return on Equity | Revenue-Display | Revenue-Actual | Revenue | Quarterly Revenue Growth | EBITDA-Display | EBITDA-Actual | EBITDA | Diluted EPS | Quarterly Earnings Growth | Total Cash-Display | Total Cash-Actual | Total Cash | Total Debt-Display | Total Debt-Actual | Total Debt | Total Debt/Equity | Current Ratio | Operating Cash Flow-Display | Operating Cash Flow-Actual | Operating Cash Flow | Levered Free Cash Flow-Display | Levered Free Cash Flow-Actual | Levered Free Cash Flow | % Held by Insiders | % Held by Institutions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.57 B | 61570000000.0 | 61.57 | 55.26 B | 55260000000.0 | 55.26 | 14.69 | 13.37 | 0.9 | 4.56 | 2.1 | 3.89 | 10.39 | 31.07% | 26.91% | 7.31% | 15.95% | 14.2 B | 14200000000.0 | 14.2 | 10.30% | 4.63 B | 4630000000.0 | 4.63 | 38.35 | -20.90% | 9.01 B | 9010000000.0 | 9.01 | 2.94 B | 2940000000.0 | 2.94 | 0.1001 | 4.73 | 4.42 B | 4420000000.0 | 4.42 | 2.64 B | 2640000000.0 | 2.64 | 1.58% | 91.78% |
source:https://finance.yahoo.com/REGN/key-statistics
source:https://www.google.com/finance/quote/REGN:NASDAQ
source:https://finance.yahoo.com/REGN/analysis
source:https://finance.yahoo.com/REGN/fair-value
source:https://www.nasdaq.com/market-activity/stocks/REGN/price-earnings-peg-ratios
| Key | Weighted | 5D | 1M | 3M | 6M | 1Y | 3Y | 10Y |
|---|---|---|---|---|---|---|---|---|
| Upside % (high) | 19.44% | 2.68% (614.83) | 7.46% (643.43) | 24.97% (748.29) | 70.44% (1020.5492) | 102.28% (1211.1999) | 102.28% (1211.1999) | 102.28% (1211.1999) |
| Downside % (low) | 10.59% | 5.61% (565.14) | 12.15% (525.99) | 12.15% (525.99) | 12.15% (525.99) | 12.15% (525.99) | 12.15% (525.99) | 54.68% (271.37) |
| Spread % | 8.85% | -2.93% | -4.69% | 12.82% | 58.29% | 90.13% | 90.13% | 47.61% |
REGN's price used for computing the stats is 598.76 as on date
| Key | Today | 5D | 2W | 1M | 3M | 6M | 1Y | 3Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|
| Last Price-Trend PrevClose | -1.98% | 6.64% | 8.04% | -6.46% | -11.95% | -41.1% | -33.95% | -15.2% | 29.26% |
| Last Price | 598.76 | 598.76 | 598.76 | 598.76 | 598.76 | 598.76 | 598.76 | 598.76 | 598.76 |
| Trend-Previous Close | 610.86 | 561.49 | 554.18 | 640.14 | 680.03 | 1016.53 | 906.54 | 706.11 | 463.22 |
REGN's symbol cumulative return percent is computed basis data from date
| 5D | 2W | 1M | 3M | 6M | 1Y | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5D window |
5D Opportunity:
SELL-APPROACHING
returns:
6.64%
(10.67%),
p.close: 561.49
entry:
621.41,
exit:
621.41,
min.ret:
-0.0%
Using: 5D trend, 0 Days Left
|
5D Opportunity:
SELL-APPROACHING
returns:
6.64%
(9.19%),
p.close: 561.49
entry:
613.1,
exit:
616.83,
min.ret:
-0.61%
Using: 5D trend, 0 Days Left
|
5D Opportunity:
SELL-APPROACHING
returns:
6.64%
(6.66%),
p.close: 561.49
entry:
598.91,
exit:
602.03,
min.ret:
-0.52%
Using: 5D trend, 0 Days Left
|
5D Opportunity:
SELL-APPROACHING
returns:
6.64%
(7.02%),
p.close: 561.49
entry:
600.88,
exit:
597.71,
min.ret:
0.53%
Using: 5D trend, 0 Days Left
|
5D Opportunity:
SELL-ACTIVE
returns:
6.64%
(5.4%),
p.close: 561.49
entry:
591.82,
exit:
589.29,
min.ret:
0.43%
Using: 5D trend, 0 Days Left
|
5D Opportunity:
SELL-ACTIVE
returns:
6.64%
(5.29%),
p.close: 561.49
entry:
591.17,
exit:
593.09,
min.ret:
-0.33%
Using: 5D trend, 0 Days Left
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2W window |
2W Opportunity:
SELL-APPROACHING
returns:
8.04%
(9.5%),
p.close: 554.18
entry:
606.81,
exit:
620.14,
min.ret:
-2.2%
Using: 2W trend, 0 Days Left
|
2W Opportunity:
SELL-ACTIVE
returns:
8.04%
(6.41%),
p.close: 554.18
entry:
589.71,
exit:
585.5,
min.ret:
0.71%
Using: 2W trend, 0 Days Left
|
2W Opportunity:
SELL-APPROACHING
returns:
8.04%
(8.35%),
p.close: 554.18
entry:
600.46,
exit:
587.94,
min.ret:
2.08%
Using: 2W trend, 0 Days Left
|
2W Opportunity:
SELL-ACTIVE
returns:
8.04%
(6.67%),
p.close: 554.18
entry:
591.12,
exit:
579.6,
min.ret:
1.95%
Using: 2W trend, 0 Days Left
|
2W Opportunity:
SELL-ACTIVE
returns:
8.04%
(7.3%),
p.close: 554.18
entry:
594.65,
exit:
595.19,
min.ret:
-0.09%
Using: 2W trend, 0 Days Left
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1M window |
1M Opportunity:
returns:
-6.46%
(-23.32%),
p.close: 640.14
entry:
490.85,
exit:
498.18,
min.ret:
1.49%
Using: 1M trend, 0 Days Left
|
1M Opportunity:
returns:
-6.46%
(-18.43%),
p.close: 640.14
entry:
522.19,
exit:
533.02,
min.ret:
2.07%
Using: 1M trend, 0 Days Left
|
1M Opportunity:
returns:
-6.46%
(-20.95%),
p.close: 640.14
entry:
506.06,
exit:
509.41,
min.ret:
0.66%
Using: 1M trend, 0 Days Left
|
1M Opportunity:
returns:
-6.46%
(-17.62%),
p.close: 640.14
entry:
527.36,
exit:
526.66,
min.ret:
-0.13%
Using: 1M trend, 0 Days Left
|
REGN's symbol current price is 598.76 (-1.98%) as on . Yesterday's close was 610.86. It's return velocities are computed basis data from date .